MetaCap

Aspen Neuroscience (ASPE) vs Phathom Pharmaceuticals (PHAT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Phathom Pharmaceuticals is the larger company by market cap ($378.8 million vs $361.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASPE-16.59%PHAT-18.82%
+11%-6%-23%
Oct 30, 20261 yearNov 20, 2026
ASPE-16.59%PHAT-18.82%
+7%-7%-20%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASPE versus PHAT key metrics
MetricASPEPHAT
Share price$12.42$4.66
Market cap$361.16M$378.82M
1-day change+0.24%-8.27%
YTD return—-71.91%
1-year return—-68.93%
5-year return—-76.46%
Forward P/E—5.18
EPS (TTM)$-4.89$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$175.11M
Revenue growth (YoY)—+216.93%
Net income (latest FY)—$-221.25M
Gross margin—87.09%
Operating margin—-91.36%
Net margin—-126.35%
52-week high$14.90$18.31
52-week low$11.20$4.62
Distance from 52-week high-16.64%-74.55%
Analyst consensus—strong_buy
Avg. price target upside—+321.67%
Average volume352.42K1.45M
Shares outstanding29.08M81.29M
Employees120371
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aspen Neuroscience

ASPE stock →

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Phathom Pharmaceuticals

PHAT stock →

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.

Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees

ASPE vs PHAT FAQ

Which is bigger, Aspen Neuroscience or Phathom Pharmaceuticals?

Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $378.82M compared with $361.16M for Aspen Neuroscience (ASPE).

Are Aspen Neuroscience and Phathom Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons